Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Table 2 Estimated odds of serious infection for treatment strategies compared to placebo

Treatment strategy	Comparator	Odds ratio	Standard error	95% Confidence interval
Infliximab	Placebo	1.36	0.45	0.57	3.27
Adalimumab	Placebo	0.77	0.36	0.38	1.56
Certolizumab pegol	Placebo	2.37	0.50	0.88	6.38
Natalizumab	Placebo	0.80	0.40	0.37	1.73
Ustekinumab	Placebo	0.40	0.49	0.16	1.05
Vedolizumab	Placebo	0.75	0.38	0.36	1.58
Golimumab	Placebo	1.71	0.67	0.46	6.31
Methotrexate	Placebo	0.52	1.28	0.04	6.34
Azathioprine/6MP	Placebo	1.43	0.61	0.43	4.76
Prednisone	Placebo	1.92	0.85	0.36	10.21
Budesonide	Placebo	1.99	1.65	0.08	50.97
Aminosalicylate	Placebo	1.37	1.40	0.09	21.47
Antibiotic	Placebo	1.01	1.07	0.12	8.34
Tacrolimus	Placebo	1.19	2.02	0.02	62.32
Methotrexate + prednisone	Placebo	2.94	1.45	0.17	50.23
Azathioprine/6MP + prednisone	Placebo	2.37	1.76	0.07	75.25
Aminosalicylate + prednisone	Placebo	7.32	2.41	0.06	832.34
Budesonide + prednisone	Placebo	1.89	2.18	0.03	135.88
MMF + prednisone	Placebo	4.14	2.07	0.07	241.50
Infliximab + azathioprine/6MP	Placebo	1.10	0.65	0.31	3.97
Azathioprine/6MP + aminosalicylate	Placebo	1.35	2.11	0.02	83.66
Natalizumab + inflximab	Placebo	0.71	2.06	0.01	40.65
Infliximab + azathioprine/6MP + prednisone	Placebo	0.32	2.33	0.00	30.40

ISSN: 1471-230X